Accessibility Menu
enGene logo

enGene(NASDAQ) ENGN

Current Price$1.92
Market Cap$129.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-81%
5 YearN/A
1 Year-50%
1 Month+12%
enGene last closing stock price
MetricPriceDate
Last closeUSD 1.932026-07-21
enGene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.85%USD 1.902026-07-14
1 month+12.21%USD 1.722026-06-18
3 month-77.4%USD 8.542026-04-22
Year to date-78.63%USD 9.032025-12-31
1 year-49.87%USD 3.852025-07-21
3 year-82.08%USD 10.772023-07-21
Since inception-81.03%USD 9.862022-02-01

enGene Financials at a Glance

Market Cap

$129.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$66.40M

EPS (TTM)

-$2.18

P/E Ratio

-0.88

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$1.92

Volume

259,892.461

Open

$1.87

Previous Close

$1.93

Daily Range

$1.86 - $1.94

52-Week Range

$1.40 - $12.25

Estimated Earnings Date

Sep 14, 2026

ENGN News

Foolcom-Featured.png

enGene Posts 78% Expense Jump in Q3

Motley Fool Markets TeamSep 11, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About enGene

enGene develops genetic medicines for people with bladder cancer. Its main therapy aims to help patients who do not respond to standard treatments. The company’s work focuses on making these therapies easier to use in clinics.

What’s in the enGene Toolbox?

  • Detalimogene voraplasmid (EG-70): Non-viral gene therapy for bladder cancer patients unresponsive to standard care; 0% of revenue as of 2025.
  • DDX Gene Delivery Platform: Technology for delivering genetic material to mucosal tissues; supports future therapies; 0% of revenue.
  • LEGEND Clinical Program: Phase 1/2 trial for EG-70 in several bladder cancer patient groups; no revenue generated.
  • Preclinical Research: Early-stage work to expand EG-70 and DDX platform to other cancers; no revenue yet.

Growth Moves: enGene’s Expansion Playbook

  • Amended LEGEND protocol in September 2024 to improve patient evaluation.
  • Raised $200 million in February 2024 and $60.1 million in October 2024 through PIPE financings.
  • Entered or expanded manufacturing with external partners to prepare for future commercialization.
  • Entered U.S. market with office in Waltham, Massachusetts in 2024.

What Makes enGene Stand Out?

enGene’s technology delivers genetic therapies directly to affected tissues, avoiding viruses. Its therapies are designed for use in standard clinics, not just hospitals. The company holds patents covering its products and manufacturing methods into the 2030s and 2040s.

Five Things You Need to Know

  • No product revenue reported for QQ3 2025, QQ3 2024, or QQ3 2023.
  • Net loss was $-29 million in QQ3 2025, down 104.9% from QQ3 2024.
  • Cash and equivalents were $173 million as of October 31, 2024.
  • Operating expenses rose to $62.3 million in 2024, up from $26.1 million in 2023.
  • Raised $265.7 million in financing in 2024, up from $86.1 million in 2023.

Bottom Line

enGene focuses on genetic therapies for bladder cancer, with no product sales yet. The company relies on innovation, external funding, and a single lead therapy in clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

82

CEO

Ronald Harold Wilfred Cooper

Website

www.engene.com

Headquarters

Montreal, QC H4R 2P1, CA

ENGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-29.34%

Return on Capital

-61.74%

Return on Assets

-21.59%

Earnings Yield

-1.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$129.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

66.99M

Volume

259.89K

Avg. Volume

1.91M

Financials (TTM)

Gross Profit

-$369.00K

Operating Income

-$68.65M

EBITDA

-$125.94M

Operating Cash Flow

-$110.00M

Capital Expenditure

-$1.39M

Free Cash Flow

-$111.39M

Cash & ST Invst.

$258.47M

Total Debt

$33.35M

enGene Performance Analysis

enGene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-10-31USD 0N/A
20242024-10-31USD 0N/A
20252025-10-31USD 0N/A
enGene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31N/A
Q42025-10-31N/A
Q12026-01-31N/A
Q22026-04-30N/A
enGene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.00N/A
20232023-10-31USD -151.22N/A
20242024-10-31USD -1.46-99.0%
20252025-10-31USD -2.2957.2%
enGene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31-211.8%
Q42025-10-31-29.8%
Q12026-01-3140.5%
Q22026-04-30197.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$180.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$129.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.58M

N/A

Employees

82

N/A

Net Income

$30.23M

+217.1%

EBITDA

-$31.79M

-28.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$258.47M

+18.9%

Total Debt

$33.35M

+31.5%

Accounts Receivable

$2.92M

+448.2%

Inventory

$0.00

N/A

Long Term Debt

$30.87M

+44.5%

Short Term Debt

$2.48M

-38.0%

Return on Assets

-21.59%

N/A

Return on Invested Capital

-24.00%

N/A

Free Cash Flow

-$30.60M

-33.1%

Operating Cash Flow

-$30.50M

-32.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KRROKorro Bio, Inc.
$11.96+4.00%
ACIUAC Immune S.A.
$2.30+2.22%
ALTAltimmune, Inc.
$2.82+0.36%
CLLSCellectis S.A.
$2.69+3.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.66+0.11%
PATHUiPath
$12.04-0.01%
TAT&T
$22.26+0.01%
MARAMara Holdings
$12.25+0.05%

Questions About ENGN

What is the current price of enGene?

enGene is trading at $1.93 per share.

What is the 52-week range for enGene?

Over the past 52 weeks, enGene has traded between $1.40 and $12.25.

How much debt does enGene have?

As of the most recent reporting period, enGene reported total debt of $33.35M.

How much cash does enGene have on hand?

enGene reported $29.83M in cash and cash equivalents in its most recent financial results.

What is enGene’s dividend yield?

enGene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services